SCHEMBL6468154

SCHEMBL6468154

CNC(=O)Nc1cn(-c2cccc(Br)c2)nc1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.50
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
ATM Q13315 1/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 1/20 0.44
ITK Q08881 1/20 0.41
IRAK4 Q9NWZ3 2/20 0.39
IKBKB O14920 1/20 0.39
PARP1 P09874 1/20 0.38
RECQL P46063 1/20 0.37
PDE4A P27815 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18039550 0.88 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6470432 0.88 SMN1; SMN2 (0.51) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL18039469 0.88 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6468166 0.86 SMN1; SMN2 (0.46) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6506408 0.85 HTT (0.45) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL18039515 0.82 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL28192182 0.80 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6499185 0.78 ALDH1A1 (0.37) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL6510229 0.78 IRAK4 (0.39) SMN1; SMN2KMT2AALDH1A1KDM4EHTT
SCHEMBL6467427 0.77 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3262035-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2018-01-03 EP disclosed
CN-107406427-A Alkynyl alcohols and methods of use thereof 豪夫迈·罗氏有限公司 2017-11-28 CN disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 WO disclosed
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
WO-2005037797-A1 SUBSTITUTED PYRAZOLE UREA COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2005-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 SMN1; SMN2 3519/4885MEN1 4599/4885KMT2A 3219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.